




# PHARMACEUTICAL 2023

Atreca Inc.  
Rank 267 of 446





# PHARMACEUTICAL 2023

Atreca Inc.  
Rank 267 of 446



The relative strengths and weaknesses of Atreca Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Atreca Inc. compared to the market average is the variable Property and Equipment, increasing the Economic Capital Ratio by 51% points. The greatest weakness of Atreca Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 97% points.

The company's Economic Capital Ratio, given in the ranking table, is 33%, being 11% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	78,026
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	16,293
Liabilities, Non-Current	60,331
Other Assets	39,032
Other Compr. Net Income	0
Other Expenses	449
Other Liabilities	0
Other Net Income	817
Other Revenues	770
Property and Equipment	37,972
Research and Development	66,829
Selling, General and Administrative Expense	31,466

Output Variable	Value in 1000 USD
Assets	155,030
Liabilities	76,624
Expenses	98,744
Revenues	770
Stockholders Equity	78,406
Net Income	-97,157
Comprehensive Net Income	-97,157
Economic Capital Ratio	33%